Overview

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin